CD9 and infection: Survival rates at 32 days post-infection were 40% for the bivalent AdV-MIC3-ROP9 vaccine, 30% for the trivalent and AdV-SAG2-MIC3 vaccines, 10% in the AdV-SAG2-ROP9, and 0% in the monovalent vaccines, although all groups did have significantly longer survival times than the non-vaccinated controls.